{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:20:41Z","timestamp":1773922841028,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,5,23]],"date-time":"2015-05-23T00:00:00Z","timestamp":1432339200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00198-015-3175-1","type":"journal-article","created":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T09:20:06Z","timestamp":1432286406000},"page":"2685-2693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical efficacy and safety of monthly oral ibandronate 100\u00a0mg versus monthly intravenous ibandronate 1\u00a0mg in Japanese patients with primary osteoporosis"],"prefix":"10.1007","volume":"26","author":[{"name":"for the MOVEST Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Shinomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Asao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Mizunuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,23]]},"reference":[{"key":"3175_CR1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut III","year":"2004","unstructured":"Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE) (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"3175_CR2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1210\/jc.2006-1415","volume":"92","author":"WD Leslie","year":"2007","unstructured":"Leslie WD, Tsang JF, Caetano PA, Lix LM, Manitoba Bone Density Program (2007) Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 92:77\u201381","journal-title":"J Clin Endocrinol Metab"},{"key":"3175_CR3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","volume":"65","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654\u2013661","journal-title":"Ann Rheum Dis"},{"key":"3175_CR4","first-page":"488","volume":"35","author":"JA Eisman","year":"2008","unstructured":"Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35:488\u2013497","journal-title":"J Rheumatol"},{"key":"3175_CR5","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","volume":"54","author":"PD Delmas","year":"2006","unstructured":"Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838\u20131846","journal-title":"Arthritis Rheum"},{"key":"3175_CR6","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00198-011-1773-0","volume":"23","author":"PD Miller","year":"2012","unstructured":"Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanauskaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P (2012) Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int 23:1747\u20131756","journal-title":"Osteoporos Int"},{"key":"3175_CR7","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00198-011-1793-9","volume":"23","author":"G Bianchi","year":"2012","unstructured":"Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D (2012) Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporos Int 23:1769\u20131778","journal-title":"Osteoporos Int"},{"key":"3175_CR8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1185\/030079908X253717","volume":"24","author":"ST Harris","year":"2008","unstructured":"Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237\u2013245","journal-title":"Curr Med Res Opin"},{"key":"3175_CR9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00198-008-0653-8","volume":"20","author":"A Cranney","year":"2009","unstructured":"Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, Miller PD, Papapoulos S, Reginster JY, Sambrook PN, Silverman S, Siris E, Adachi JD (2009) Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 20:291\u2013297","journal-title":"Osteoporos Int"},{"key":"3175_CR10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00198-013-2518-z","volume":"25","author":"PD Miller","year":"2014","unstructured":"Miller PD, Recker RR, Harris S, Silverman S, Felsenberg D, Reginster J, Day DM, Barr C, Masanauskaite D (2014) Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int 25:349\u2013357","journal-title":"Osteoporos Int"},{"key":"3175_CR11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-013-9734-6","volume":"93","author":"T Nakamura","year":"2013","unstructured":"Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H, MOVER Study Group (2013) Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg\/month intravenous ibandronate versus 2.5 mg\/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int 93:137\u2013146","journal-title":"Calcif Tissue Int"},{"key":"3175_CR12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s001980050214","volume":"10","author":"M Shiraki","year":"1999","unstructured":"Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10:183\u2013192","journal-title":"Osteoporos Int"},{"key":"3175_CR13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00774-005-0616-5","volume":"23","author":"S Uchida","year":"2005","unstructured":"Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, Fukunaga M, Tomomitsu T, Ohashi Y, Nakamura T (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 23:382\u2013388","journal-title":"J Bone Miner Metab"},{"key":"3175_CR14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s001980200135","volume":"13","author":"M Fukunaga","year":"2002","unstructured":"Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H, Risedronate Phase III Research Group (2002) A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 13:971\u2013979","journal-title":"Osteoporos Int"},{"key":"3175_CR15","first-page":"469","volume":"22","author":"K Kushida","year":"2004","unstructured":"Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, Ohashi Y, Orimo H (2004) A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab 22:469\u2013478","journal-title":"J Bone Miner Metab"},{"key":"3175_CR16","doi-asserted-by":"crossref","unstructured":"Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y, Risedronate Phase III Research Group (2006) Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 24:405\u2013413","DOI":"10.1007\/s00774-006-0706-z"},{"key":"3175_CR17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bone.2013.10.017","volume":"59","author":"H Hagino","year":"2014","unstructured":"Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T (2014) Efficacy, tolerability and safety of once-monthly administration of 75 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5 mg once-daily dosage regimen. Bone 59:44\u201352","journal-title":"Bone"},{"issue":"Suppl 1","key":"3175_CR18","first-page":"S333","volume":"22","author":"T Nakamura","year":"2007","unstructured":"Nakamura T, Mizunuma H, Itabashi A, Yamane H, Hannita T, Karube M, Takeuchi K, Ikegami R, Okamoto S, Hasunuma T, Kumagai Y (2007) Monthly oral ibandronate is well tolerated and efficacious in Japanese osteoporotic subject. J Bone Miner Res 22(Suppl 1):S333","journal-title":"J Bone Miner Res"},{"key":"3175_CR19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s007740170001","volume":"19","author":"H Orimo","year":"2001","unstructured":"Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331\u2013337","journal-title":"J Bone Miner Metab"},{"key":"3175_CR20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2008.10.052","volume":"44","author":"AI Sebba","year":"2009","unstructured":"Sebba AI, Emkey RD, Kohles JD, Sambrook PN (2009) Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone 44:423\u2013427","journal-title":"Bone"},{"key":"3175_CR21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00223-010-9403-y","volume":"87","author":"PD Miller","year":"2010","unstructured":"Miller PD, Delmas PD, Huss H, Patel KM, Schimmer RC, Adami S, Recker RR (2010) Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate. Calcif Tissue Int 87:305\u2013313","journal-title":"Calcif Tissue Int"},{"key":"3175_CR22","doi-asserted-by":"crossref","unstructured":"Nakai K, Tobinai M, Hashimoto J, Iida S, Kawanishi T (2014) The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties. Eur J Drug Metab Pharmacokinet doi: 10.1007\/s13318-014-0242-5","DOI":"10.1007\/s13318-014-0242-5"},{"key":"3175_CR23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","volume":"44","author":"J Barrett","year":"2004","unstructured":"Barrett J, Worth E, Bauss F, Epstein S (2004) Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 44:951\u2013965","journal-title":"J Clin Pharmacol"},{"key":"3175_CR24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00774-003-0458-y","volume":"22","author":"Y Ogura","year":"2004","unstructured":"Ogura Y, Gonsho A, Cyong JC, Orimo H (2004) Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. J Bone Miner Metab 22:111\u2013119","journal-title":"J Bone Miner Metab"},{"key":"3175_CR25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00198-002-1369-9","volume":"14","author":"M Shiraki","year":"2003","unstructured":"Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H (2003) A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int 14:225\u2013234","journal-title":"Osteoporos Int"},{"key":"3175_CR26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/00912700022008928","volume":"40","author":"DY Mitchell","year":"2000","unstructured":"Mitchell DY, Eusebio RA, Sacco-Gibson NA, Pallone KA, Kelly SC, Nesbitt JD, Brezovic CP, Thompson GA, Powell JH (2000) Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol 40:258\u2013265","journal-title":"J Clin Pharmacol"},{"key":"3175_CR27","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","volume":"21","author":"JA Cramer","year":"2005","unstructured":"Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453\u20131460","journal-title":"Curr Med Res Opin"},{"key":"3175_CR28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00198-009-0930-1","volume":"21","author":"FE Cott\u00e9","year":"2010","unstructured":"Cott\u00e9 FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145\u2013155","journal-title":"Osteoporos Int"},{"key":"3175_CR29","doi-asserted-by":"crossref","unstructured":"Cooper A, Drake J, Brankin E, (Fi - this is what's on PubMed and in the original manuscript, so not sure why the journal has flipped the words around) (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896\u2013905","DOI":"10.1111\/j.1742-1241.2006.01059.x"},{"key":"3175_CR30","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1185\/030079905X74862","volume":"21","author":"R Emkey","year":"2005","unstructured":"Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895\u20131903","journal-title":"Curr Med Res Opin"},{"key":"3175_CR31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jbspin.2007.07.011","volume":"75","author":"P Hadji","year":"2008","unstructured":"Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303\u2013310","journal-title":"Joint Bone Spine"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-015-3175-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3175-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3175-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T14:12:20Z","timestamp":1551190340000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-015-3175-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,23]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["3175"],"URL":"https:\/\/doi.org\/10.1007\/s00198-015-3175-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,23]]}}}